FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280596494> ?p ?o ?g. }

• W4280596494 abstract "Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical trial. The purpose of this study was to evaluate the median change from baseline in conventional serologic biomarkers in subgroups and the overall population of baricitinib-treated patients with SLE, and the SLE Responder Index-4 (SRI-4) response by normalization of anti-dsDNA.Data were assessed from the phase II trial I4V-MC-JAHH (NCT02708095). The median change from baseline in anti-dsDNA, IgG, and other conventional serologic markers was evaluated over time in patients who had elevated levels of markers at baseline, and in all patients for IgG. Median change from baseline for baricitinib treatments were compared with placebo. Among patients who were anti-dsDNA positive at baseline, SRI-4 responder rate was compared for those who stayed positive or achieved normal levels by week 24.Significant decreases of anti-dsDNA antibodies were observed in response to baricitinib 2 mg and 4 mg compared to placebo beginning at weeks 2 (baricitinib 2 mg = - 14.3 IU/mL, placebo = 0.1 IU/mL) and 4 (baricitinib 4 mg = - 17.9 IU/mL, placebo = 0.02 IU/mL), respectively, continuing through week 24 (baricitinib 2 mg = - 29.6 IU/mL, baricitinib 4 mg = - 15.1 IU/mL, placebo=3.0 IU/mL). Significant reductions from baseline of IgG levels were found for baricitinib 4 mg-treated patients compared to placebo at weeks 12 (baricitinib 4 mg = - 0.65 g/L, placebo = 0.09 g/L) and 24 (baricitinib 4 mg = - 0.60 g/L, placebo = - 0.04 g/L). For patients who were anti-dsDNA positive at baseline, no relationship between achieving SRI-4 responder and normalization of anti-dsDNA was observed by week 24.Baricitinib treatment resulted in a rapid and sustained significant decrease in anti-dsDNA antibodies compared to placebo among those with positive anti-dsDNA antibodies at baseline, as well as a significant decrease in IgG levels in the 4 mg group at weeks 12 and 24. These data suggest that baricitinib may influence B cell activity in SLE. Further studies are needed to evaluate if reductions in anti-dsDNA levels with baricitinib treatment reflect the impact of baricitinib on B cell activity.NCT02708095 ." @default.
• W4280596494 created "2022-05-22" @default.
• W4280596494 creator A5001548815 @default.
• W4280596494 creator A5012009272 @default.
• W4280596494 creator A5013318666 @default.
• W4280596494 creator A5032266570 @default.
• W4280596494 creator A5062689189 @default.
• W4280596494 creator A5070413478 @default.
• W4280596494 creator A5071430304 @default.
• W4280596494 creator A5079090212 @default.
• W4280596494 creator A5085560065 @default.
• W4280596494 date "2022-05-16" @default.
• W4280596494 modified "2023-10-18" @default.
• W4280596494 title "Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial" @default.
• W4280596494 cites W1537631996 @default.
• W4280596494 cites W1583798678 @default.
• W4280596494 cites W1777024811 @default.
• W4280596494 cites W1853052534 @default.
• W4280596494 cites W1966335538 @default.
• W4280596494 cites W1966755507 @default.
• W4280596494 cites W1968816450 @default.
• W4280596494 cites W1970308473 @default.
• W4280596494 cites W1979432001 @default.
• W4280596494 cites W1989204738 @default.
• W4280596494 cites W1999218213 @default.
• W4280596494 cites W2040213563 @default.
• W4280596494 cites W2061867553 @default.
• W4280596494 cites W2152000030 @default.
• W4280596494 cites W2159860161 @default.
• W4280596494 cites W2163087340 @default.
• W4280596494 cites W2219152942 @default.
• W4280596494 cites W2412228566 @default.
• W4280596494 cites W2508212658 @default.
• W4280596494 cites W2551404503 @default.
• W4280596494 cites W2618503014 @default.
• W4280596494 cites W2752410678 @default.
• W4280596494 cites W2766476830 @default.
• W4280596494 cites W2766830060 @default.
• W4280596494 cites W2767394258 @default.
• W4280596494 cites W2810369524 @default.
• W4280596494 cites W2883700530 @default.
• W4280596494 cites W2914307879 @default.
• W4280596494 cites W2936925908 @default.
• W4280596494 cites W2962616530 @default.
• W4280596494 cites W2965565685 @default.
• W4280596494 cites W2994924932 @default.
• W4280596494 cites W3049003103 @default.
• W4280596494 cites W3092452074 @default.
• W4280596494 cites W3163373663 @default.
• W4280596494 doi "https://doi.org/10.1186/s13075-022-02794-x" @default.
• W4280596494 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35578304" @default.
• W4280596494 hasPublicationYear "2022" @default.
• W4280596494 type Work @default.
• W4280596494 citedByCount "12" @default.
• W4280596494 countsByYear W42805964942022 @default.
• W4280596494 countsByYear W42805964942023 @default.
• W4280596494 crossrefType "journal-article" @default.
• W4280596494 hasAuthorship W4280596494A5001548815 @default.
• W4280596494 hasAuthorship W4280596494A5012009272 @default.
• W4280596494 hasAuthorship W4280596494A5013318666 @default.
• W4280596494 hasAuthorship W4280596494A5032266570 @default.
• W4280596494 hasAuthorship W4280596494A5062689189 @default.
• W4280596494 hasAuthorship W4280596494A5070413478 @default.
• W4280596494 hasAuthorship W4280596494A5071430304 @default.
• W4280596494 hasAuthorship W4280596494A5079090212 @default.
• W4280596494 hasAuthorship W4280596494A5085560065 @default.
• W4280596494 hasBestOaLocation W42805964941 @default.
• W4280596494 hasConcept C126322002 @default.
• W4280596494 hasConcept C142724271 @default.
• W4280596494 hasConcept C159654299 @default.
• W4280596494 hasConcept C198451711 @default.
• W4280596494 hasConcept C203014093 @default.
• W4280596494 hasConcept C204787440 @default.
• W4280596494 hasConcept C27081682 @default.
• W4280596494 hasConcept C2908647359 @default.
• W4280596494 hasConcept C45189115 @default.
• W4280596494 hasConcept C71924100 @default.
• W4280596494 hasConcept C90924648 @default.
• W4280596494 hasConcept C99454951 @default.
• W4280596494 hasConceptScore W4280596494C126322002 @default.
• W4280596494 hasConceptScore W4280596494C142724271 @default.
• W4280596494 hasConceptScore W4280596494C159654299 @default.
• W4280596494 hasConceptScore W4280596494C198451711 @default.
• W4280596494 hasConceptScore W4280596494C203014093 @default.
• W4280596494 hasConceptScore W4280596494C204787440 @default.
• W4280596494 hasConceptScore W4280596494C27081682 @default.
• W4280596494 hasConceptScore W4280596494C2908647359 @default.
• W4280596494 hasConceptScore W4280596494C45189115 @default.
• W4280596494 hasConceptScore W4280596494C71924100 @default.
• W4280596494 hasConceptScore W4280596494C90924648 @default.
• W4280596494 hasConceptScore W4280596494C99454951 @default.
• W4280596494 hasFunder F4320321526 @default.
• W4280596494 hasIssue "1" @default.
• W4280596494 hasLocation W42805964941 @default.
• W4280596494 hasLocation W42805964942 @default.
• W4280596494 hasLocation W42805964943 @default.
• W4280596494 hasOpenAccess W4280596494 @default.
• W4280596494 hasPrimaryLocation W42805964941 @default.
• W4280596494 hasRelatedWork W1988920656 @default.
• W4280596494 hasRelatedWork W2029727153 @default.

• next